{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:53:03Z","timestamp":1768881183881,"version":"3.49.0"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>No information is available on the efficacy of ferric carboxymaltose (FCM) in real-world CKD patients outside the hemodialysis setting. We prospectively followed 59 non-hemodialysis CKD patients with iron deficient anemia (IDA: hemoglobin &lt;12.0\/&lt;13.5 g\/dL in women\/men and TSAT &lt; 20% and\/or ferritin &lt; 100 ng\/mL) who were intolerant or non-responders to oral iron. Patients received ferric carboxymaltose (FCM) (single dose of 500 mg) followed by additional doses if iron deficiency persisted. We evaluated efficacy of FCM in terms of increase of hemoglobin, ferritin, and TSAT levels. Direct and indirect costs of FCM were also analyzed in comparison with a hypothetical scenario where same amount of iron as ferric gluconate (FG) was administered intravenously. During the 24 weeks of study, 847 \u00b1 428 mg of FCM per patient were administered. IDA improved after four weeks of FCM and remained stable thereafter. At week-24, mean change (95%CI) from baseline of hemoglobin, ferritin and TSAT were +1.16 g\/dL (0.55\u20131.77), +104 ng\/mL (40\u2013168) and +9.5% (5.8\u201313.2), respectively. These changes were independent from ESA use and clinical setting (non-dialysis CKD, peritoneal dialysis and kidney transplant). Among ESA-treated patients (n = 24), ESA doses significantly decreased by 26% with treatment and stopped either temporarily or persistently in nine patients. FCM, compared to a FG-based scenario, was associated with a cost saving of 288 euros\/patient\/24 weeks. Saving was the same in ESA users\/non-users. Therefore, in non-hemodialysis CKD patients, FCM effectively corrects IDA and allows remarkable cost savings in terms of societal, healthcare and patient perspective.<\/jats:p>","DOI":"10.3390\/jcm10061322","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T14:08:16Z","timestamp":1616508496000},"page":"1322","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Ferric Carboxymatose in Non-Hemodialysis CKD Patients: A Longitudinal Cohort Study"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2089","authenticated-orcid":false,"given":"Roberto","family":"Minutolo","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Berto","sequence":"additional","affiliation":[{"name":"Certara Italy, 20124 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elena","family":"Liberti","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Peruzzu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-4597","authenticated-orcid":false,"given":"Silvio","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Netti","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Garofalo","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Conte","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0182","authenticated-orcid":false,"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Campania, Luigi Vanvitelli, 80138 Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2323","authenticated-orcid":false,"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Dialysis, Sant\u2019Anna Hospital, ASST Lariana, 22042 Como, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Alessandro Manzoni Hospital, 23900 Lecco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/ndt\/gft338","article-title":"Anaemia management in non-dialysis chronic kidney dis-ease (CKD) patients: A multicentre prospective study in renal clinics","volume":"28","author":"Minutolo","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/ckj\/sfx060","article-title":"Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: A national study","volume":"11","author":"Stack","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_3","first-page":"189","article-title":"Prevalence of anaemia and its clinical man-agement in patients with stages 3-5 chronic kidney disease not on dialysis in Catalonia: MICENAS I study","volume":"34","author":"Ruiz","year":"2014","journal-title":"Nefrologia"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dmitrieva, O., De Lusignan, S., MacDougall, I.C., Gallagher, H., Tomson, C., Harris, K., DeSombre, T., and Goldsmith, D. (2013). Association of anaemia in primary care patients with chronic kidney disease: Cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-24"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/nep.12493","article-title":"Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study","volume":"20","author":"Iimori","year":"2015","journal-title":"Nephrology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4103\/1319-2442.265471","article-title":"Etiological spectrum of anemia in non-dialysis-dependent chronic kidney disease: A sin-gle-center study from India","volume":"30","author":"Vikrant","year":"2019","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"ref_7","first-page":"48","article-title":"Serum total iron-binding capacity and iron status in patients with non-dialysis-dependent chronic kidney disease: A cross-sectional study in Vietnam","volume":"29","author":"Thang","year":"2020","journal-title":"Asia Pac. J. Clin. Nutr."},{"key":"ref_8","unstructured":"National Clinical Guideline Centre (2020, August 18). Anaemia management in chronic kidney disease: Update 2015. NICE guideline 8. National Institute for Health and Care Excellence (NICE). Updated 2015. Available online: http:\/\/www.nice.org.uk\/guidance\/ng8."},{"key":"ref_9","unstructured":"(2012). KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. Suppl., 2, 279\u2013335."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: A European Renal Best Practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: A randomized trial of intravenous ferric car-boxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_12","first-page":"50","article-title":"[Iron deficiency in ND-CKD: From diagnosis to treatment]","volume":"34","author":"Liberti","year":"2017","journal-title":"G. Ital. Nefrol."},{"key":"ref_13","first-page":"345","article-title":"The new generation of intravenous iron: Chemistry, pharmacology, and toxicology of ferric carboxymaltose","volume":"60","author":"Funk","year":"2010","journal-title":"Arzneimittelforschung"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.ejpb.2011.03.016","article-title":"A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer\u00ae), a new intravenous iron preparation and its clinical implications","volume":"78","author":"Jahn","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_15","unstructured":"(2020, August 17). European Medicines Agency\u2014News and Events\u2014New Recommendations to Manage Risk of Allergic Reactions with Intravenous Iron-Containing Medicines. Available online: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/06\/news_detail_001833.jsp&mid=WC0b01ac058004d5c1."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"552","DOI":"10.2215\/CJN.04380808","article-title":"Epoetin Therapy and Hemoglobin Level Variability in Nondialysis Patients with Chronic Kidney Disease","volume":"4","author":"Minutolo","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"key":"ref_18","unstructured":"ISTAT (2020, August 18). Reddito Netto: Regioni e Tipo di Comune. Available online: http:\/\/dati.istat.it\/Index.aspx?QueryId=22919."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000321486","article-title":"Conversion of Darbepoetin to Low Doses of CERA Maintains Hemoglobin Levels in Non-Dialysis Chronic Kidney Disease Patients","volume":"30","author":"Minutolo","year":"2010","journal-title":"Blood Purif."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of Inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.3324\/haematol.2014.121004","article-title":"On the safety of intravenous iron, evidence trumps conjecture","volume":"100","author":"Auerbach","year":"2015","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40261-015-0361-z","article-title":"Efficacy and safety of ferric car-boxymaltose and other formulations in iron-deficient patients: A systematic review and network me-ta-analysis of randomised controlled trials","volume":"36","author":"Rognoni","year":"2016","journal-title":"Clin. Drug Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The safety of intravenous iron preparations: Systematic review and meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2010","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The REPAIR-IDA trial","volume":"29","author":"Onken","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Toblli, J.E., and Di Gennaro, F. (2015). Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125528"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ndt\/gfaa088","article-title":"Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease","volume":"36","author":"Minutolo","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2215\/CJN.01541005","article-title":"Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythro-poiesis-stimulating agents for anemia: A randomized, controlled trial","volume":"1","author":"Singh","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11255-019-02362-4","article-title":"Efficacy and safety of a low monthly dose of intravenous iron sucrose in peritoneal dialysis patients","volume":"52","author":"Mitsopoulos","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/089686080802800210","article-title":"Intravenous iron sucrose in peritoneal dialysis patients with renal anemia","volume":"28","author":"Li","year":"2008","journal-title":"Perit. Dial. Int."},{"key":"ref_31","first-page":"174","article-title":"Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: An observational study","volume":"14","author":"Paraiso","year":"2019","journal-title":"Clin. Kidney J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3747\/pdi.2018.00249","article-title":"International Anemia Prevalence and Management in Peritoneal Dialysis Patients","volume":"39","author":"Perlman","year":"2019","journal-title":"Perit. Dial. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1399-0012.2012.01602.x","article-title":"Intravenous iron supplementation after kidney transplantation","volume":"26","author":"Zingerman","year":"2012","journal-title":"Clin. Transplant."},{"key":"ref_34","first-page":"818","article-title":"Anemia Is Associated with Mortality in Kidney-Transplanted Patients?A Prospective Cohort Study","volume":"7","author":"Molnar","year":"2007","journal-title":"Arab. Archaeol. Epigr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"b4018","DOI":"10.1136\/bmj.b4018","article-title":"Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study","volume":"339","author":"Heinze","year":"2009","journal-title":"BMJ"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1399-0012.2011.01545.x","article-title":"Impact of post-transplant anemia on patient and graft survival rates after kidney transplantation: A meta-analysis","volume":"26","author":"Kamar","year":"2011","journal-title":"Clin. Transplant."},{"key":"ref_37","first-page":"CD007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"2","author":"Hodson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2215\/CJN.05390517","article-title":"Safety of intravenous iron in dialysis: A systematic review and meta-analysis","volume":"13","author":"Hougen","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1524-4733.2005.00058.x","article-title":"Economic Burden of Patients with Anemia in Selected Diseases","volume":"8","author":"Ershler","year":"2005","journal-title":"Value Heal."},{"key":"ref_40","first-page":"565","article-title":"Economic Burden of Anemia in an Insured Population","volume":"11","author":"Nissenson","year":"2005","journal-title":"J. Manag. Care Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1681\/ASN.2006030289","article-title":"Medical Costs of Untreated Anemia in Elderly Patients with Predialysis Chronic Kidney Disease","volume":"17","author":"Lefebvre","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1345\/aph.1K194","article-title":"Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease","volume":"41","author":"Maddux","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_43","first-page":"806","article-title":"Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: Results of the 2008\u201312 National Health Examination Survey","volume":"30","author":"Donfrancesco","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/j.ajkd.2008.03.002","article-title":"Detection and Awareness of Moderate to Advanced CKD by Primary Care Practitioners: A Cross-sectional Study from Italy","volume":"52","author":"Minutolo","year":"2008","journal-title":"Am. J. Kidney Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/S2352-3026(17)30230-2","article-title":"Intravenous iron: Out of sight, out of mind","volume":"5","author":"Auerbach","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40620-015-0254-5","article-title":"Impact of European medicines agency recommendations for hypersensitivity reactions on intravenous iron prescription in haemodialysis centres of the Lombardy region","volume":"29","author":"Rivera","year":"2015","journal-title":"J. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/6\/1322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:39:41Z","timestamp":1760161181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/6\/1322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["jcm10061322"],"URL":"https:\/\/doi.org\/10.3390\/jcm10061322","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,23]]}}}